Tamoxifen and informed consent/dissent.
D000367:Age Factors; D032962:Consent Forms; D030881:Disclosure; D064420:Drug-Related Side Effects and Adverse Reactions; D017041:Ethics Committees; D028744:Ethics Committees, Research; D005260:Female; D006728:Hormones; D006805:Human Experimentation; D006801:Humans; D007258:Informed Consent; D016365:Liability, Legal; D015337:Multicenter Studies as Topic; D009316:National Institutes of Health (U.S.); D009369:Neoplasms; D018579:Patient Selection; D004364:Pharmaceutical Preparations; D011315:Preventive Medicine; D012107:Research Design; D012108:Research Personnel; D035842:Research Subjects; D012306:Risk; D018570:Risk Assessment; D013629:Tamoxifen; D014481:United States; D014838:Volunteers; D014930:Women; D016387:Women's Health
Biomedical and Behavioral Research; National Cancer Institute; National Institutes of Health; Popular Approach/Source; U.S. Congress